Viracta Therapeutics Inc (NASDAQ: VIRX)’s stock price has plunge by 6.28relation to previous closing price of 0.16. Nevertheless, the company has seen a -5.90% plunge in its stock price over the last five trading sessions. globenewswire.com reported 2024-12-26 that SAN DIEGO, Dec. 26, 2024 (GLOBE NEWSWIRE) — Viracta Therapeutics, Inc. (Nasdaq: VIRX), a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide, today announced that its Board of Directors has initiated a process to explore a broad range of strategic alternatives.
Is It Worth Investing in Viracta Therapeutics Inc (NASDAQ: VIRX) Right Now?
The 36-month beta value for VIRX is at 0.70. Analysts have varying views on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for VIRX is 28.01M, and currently, shorts hold a 2.18% of that float. The average trading volume for VIRX on January 24, 2025 was 2.92M shares.
VIRX’s Market Performance
The stock of Viracta Therapeutics Inc (VIRX) has seen a -5.90% decrease in the past week, with a -19.43% drop in the past month, and a -28.40% fall in the past quarter. The volatility ratio for the week is 10.87%, and the volatility levels for the past 30 days are at 15.88% for VIRX. The simple moving average for the last 20 days is -8.06% for VIRX stock, with a simple moving average of -58.76% for the last 200 days.
Analysts’ Opinion of VIRX
Many brokerage firms have already submitted their reports for VIRX stocks, with Leerink Partners repeating the rating for VIRX by listing it as a “Market Perform.” The predicted price for VIRX in the upcoming period, according to Leerink Partners is $3 based on the research report published on August 16, 2024 of the previous year 2024.
RBC Capital Mkts, on the other hand, stated in their research note that they expect to see VIRX reach a price target of $10. The rating they have provided for VIRX stocks is “Outperform” according to the report published on February 01st, 2022.
H.C. Wainwright gave a rating of “Buy” to VIRX, setting the target price at $35 in the report published on May 03rd of the previous year.
VIRX Trading at -4.75% from the 50-Day Moving Average
After a stumble in the market that brought VIRX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -87.08% of loss for the given period.
Volatility was left at 15.88%, however, over the last 30 days, the volatility rate increased by 10.87%, as shares sank -27.42% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -6.43% lower at present.
During the last 5 trading sessions, VIRX fell by -6.06%, which changed the moving average for the period of 200-days by -84.21% in comparison to the 20-day moving average, which settled at $0.1840. In addition, Viracta Therapeutics Inc saw 5.16% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at VIRX starting from Chevallard Daniel R., who sale 3,405 shares at the price of $0.73 back on Feb 27 ’24. After this action, Chevallard Daniel R. now owns 102,306 shares of Viracta Therapeutics Inc, valued at $2,493 using the latest closing price.
Stock Fundamentals for VIRX
Current profitability levels for the company are sitting at:
- -63.97 for the present operating margin
- 0.55 for the gross margin
The net margin for Viracta Therapeutics Inc stands at -58.66. The total capital return value is set at 7.13. Equity return is now at value -370.13, with -97.94 for asset returns.
Based on Viracta Therapeutics Inc (VIRX), the company’s capital structure generated 1.64 points at debt to capital in total, while cash flow to debt ratio is standing at -2.06. The debt to equity ratio resting at -2.56. The interest coverage ratio of the stock is -14.83.
Currently, EBITDA for the company is -46.86 million with net debt to EBITDA at -0.1. When we switch over and look at the enterprise to sales, we see a ratio of 14.23. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.76.
Conclusion
In conclusion, Viracta Therapeutics Inc (VIRX) has had a bad performance lately. Opinion on the stock among analysts is mixed, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
